Corcept Therapeutics (CORT) Free Cash Flow (2010 - 2026)

Corcept Therapeutics has disclosed Free Cash Flow across 17 years of filings, most recently posting -$17.0 million for Q1 2026.

• Free Cash Flow for Q1 2026 came in at -$17.0 million, down 463.76% year-over-year; the trailing twelve-month figure through Mar 2026 was $120.1 million (down 32.13% YoY), and the FY2025 annual result was $141.8 million, down 27.71% from the prior year.
• Free Cash Flow came in at -$17.0 million for Q1 2026 at Corcept Therapeutics, down from $38.4 million in the prior quarter.
• In the past five years, Free Cash Flow ranged from a high of $71.7 million in Q3 2024 to a low of -$17.0 million in Q1 2026.
• The 5-year median for Free Cash Flow is $35.2 million (2022), against an average of $33.4 million.
• Across the five-year window, Free Cash Flow surged 984.05% in 2024 and tumbled 463.76% in 2026, its largest moves.
• Corcept Therapeutics' Free Cash Flow stood at $33.4 million in 2022, then plunged by 83.42% to $5.5 million in 2023, then soared by 984.05% to $59.9 million in 2024, then plunged by 35.94% to $38.4 million in 2025, then tumbled by 144.2% to -$17.0 million in 2026.
• The last three Free Cash Flow figures came in at -$17.0 million (Q1 2026), $38.4 million (Q4 2025), and $54.5 million (Q3 2025), per Business Quant data.